MaxCyte (NASDAQ: MXCT) — Company Overview, News & Financial Data
MaxCyte specializes in cell engineering tools to support the development of cell therapies and biotherapeutics globally.
MaxCyte
MaxCyte (NASDAQ:MXCT) specializes in cell engineering, providing essential tools and technologies that support the development and commercialization of cellular therapies and biotherapeutics. The company's cutting-edge Flow Electroporation technology and instruments facilitate the discovery, development, and manufacture of new therapies, particularly in the field of immune-oncology, cell therapy, and gene editing. MaxCyte aims to accelerate the fight against a wide range of diseases, including cancer, inherited diseases, and infectious diseases, by empowering researchers and pharmaceutical companies to unlock the full potential of their cell-based research. Serving a global clientele, MaxCyte is committed to innovation and excellence in supporting the advancement of science and medicine.
Snapshot
Operations
Products and/or services of MaxCyte
- Flow Electroporation Technology - A platform facilitating high-performance cell engineering for research, bioprocessing, and therapeutic applications.
- ExPERT instrument family - Includes ATx, STx, and GTx models tailored for advanced gene editing, cell therapy development, and protein expression optimization.
- CARMA Platform - Utilizing mRNA-based cell therapies for developing treatments against solid tumors and other diseases through a proprietary cell therapy platform.
- Life Sciences Research Instruments - Offering high-quality instruments and tools for cellular engineering, including electroporation buffers and accessories.
- Clinical and Commercial Licensing - Provides partners with access to its technology for development of cell-based therapies, including several partnerships with leading pharmaceutical companies.
- Cell Engineering Services - Custom service offerings to support the development and optimization of cell-based therapies, including process development and training.
MaxCyte executive team
- Maher MasoudPresident, CEO & Executive Director
- Parmeet AhujaChief Financial Officer
- Jay GelfmanChief Operations Officer
- Ana-Paula Martins FernandesSenior Vice President of Global Sales
- Sidharth KapileshwarChief Corporate Development Officer
- Jill MayerSenior Vice President of Human Resources
Latest news about MaxCyte
Key financials
Reported results for MaxCyte, in USD.
- Market cap
- 130M
- Revenue (TTM)
- 31.1M
- P/E ratio
- —
- EPS (diluted, TTM)
- -0.3
- Dividend yield
- —
- Profit margin
- -114.8%
| Fiscal year end | Revenue | Operating income | Net income |
|---|---|---|---|
| 33M | -45.3M | -44.6M | |
| 38.6M | -51.2M | -41.1M | |
| 41.3M | -48.3M | -37.9M | |
| 44.3M | -27.4M | -23.6M |